– UK, Oxford – Summit (AIM: SUMM), a drug discovery and development company advancing therapies for Duchenne Muscular Dystrophy (‘DMD’) and C. difficile infection (‘CDI’), announces the appointment of Mr Leopoldo Zambeletti as a Non-Executive Director.

“On behalf of the Board, I am delighted to welcome Leopoldo Zambeletti to Summit’s Board of Directors,”commented Dr Frank Armstrong, Non-Executive Chairman of Summit.  “Leopoldo is a highly respected and experienced strategic advisor to the life sciences sector and brings significant expertise in a range of areas.  We look forward to him contributing to the future strategy of Summit as we focus on advancing our two independent programmes developing potential life-changing treatments for DMD and CDI.”

Mr Zambeletti is an independent strategic advisor to the life sciences sector with expertise in a range of areas including mergers and acquisitions, equity financing and product out-licensing.  Mr Zambeletti previously worked in investment banking for 19 years where he led the European Healthcare Investment teams at JP Morgan and Credit Suisse respectively.

Leopoldo Zambeletti added, “Summit’s programmes in DMD and CDI both represent potentially significant advances in the treatment of those diseases; SMT C1100 could provide a disease-modifying treatment for all boys with DMD and SMT19969 is designed to prevent CDI recurrence, a major issue in the disease today.  I am pleased to be joining Summit under a highly experienced leadership team as we seek to bring these compounds to patients in need.”

About Leopoldo Zambeletti

Mr Leopoldo Zambeletti (aged 45) is a highly respected figure within the life sciences sector.  During a 19 year career as an investment banker, he led the European Healthcare Investment team at JP Morgan for eight years before taking up the same position at Credit Suisse for a further five years.  Since 2013 Mr Zambeletti has been an independent strategic advisor to life science companies on Merger and Acquisitions, out-licensing deals and financing strategy.  He is a Non-Executive Director of  Nogra Pharma and an advisor to the US medtech company Qardio.  He serves as a trustee to Barts and the London Charity, which helps to fund the hospitals of the Barts NHS Trust including St Bartholomew, the Royal London and the London Chest Hospitals, and he is a founder of the cultural initiative 5×15 Italy.  Mr Zambeletti started his career at KPMG as an accountant.

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Comments are closed.